Premium
Role of excision repair cross‐complementation 1 expression as a prognostic marker for response to radiotherapy in early‐stage laryngeal cancer
Author(s) -
Johung Kimberly,
Rewari Amar,
Wu Hao,
Judson Benjamin,
Contessa Joseph N.,
Haffty Bruce G.,
Decker Roy H.
Publication year - 2013
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23041
Subject(s) - ercc1 , radiation therapy , medicine , oncology , tissue microarray , stage (stratigraphy) , immunohistochemistry , chemoradiotherapy , head and neck cancer , survival analysis , cancer , multivariate analysis , head and neck squamous cell carcinoma , pathology , biology , dna repair , nucleotide excision repair , gene , paleontology , biochemistry
Background High expression of excision repair cross‐complementation 1 (ERCC1) predicts for resistance to platinum‐based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I–II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% ( p = .78) and overall survival was 68% versus 54% ( p = .65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression. © 2012 Wiley Periodicals, Inc. Head Neck, 2012